#United States #Cardiovascular #wearable technology #Brentwood #Peerbridge

Peerbridge Health Launches the COR-INSIGHT Trial

Peerbridge Health, a pioneer in cardiac diagnostics, has recently initiated the COR-INSIGHT Trial. This groundbreaking study seeks to validate the capabilities of the Peerbridge Cor® ambulatory ECG wearable in screening and diagnosing cardiovascular and cardiopulmonary conditions. As an innovative solution, this trial aims to create a paradigm shift in how we approach cardiac care, enabling more precise and accessible diagnostics, especially for underserved populations.

Significance of the COR-INSIGHT Trial

The COR-INSIGHT Trial is positioned as a pivotal development in the healthcare sector, focusing on leveraging state-of-the-art AI software as a medical device (SaMD) platforms. Specifically, the trial will utilize CardioMIND, which is designed for ECG and sleep disorder analytics, alongside CardioQSync, which employs a quantum-resonance technique to analyze cardiopulmonary and hemodynamic metrics through respiratory ECG readings.

Through this trial, Peerbridge aims to prospectively evaluate an array of diverse diagnostics derived from continuous ECG monitoring, whether performed in hospital settings or at home. The goal includes developing metrics for over 30 different heart-related conditions, addressing a significant public health issue as the American Heart Association estimates that more than 160 million adults in the U.S. are at risk.

A Broad Spectrum of Diagnostic Potential

The clinical implications of the COR-INSIGHT Trial are profound. Traditional diagnostic methods often rely on invasive procedures, imaging technologies, and biochemical tests. In contrast, the Peerbridge Cor ECG represents a non-invasive alternative that could streamline the diagnostic process significantly. Conditions including heart failure, ejection fraction severity, and sleep apnea diagnostics can be assessed using this innovative wearable technology.

Chris Darland, the CEO of Peerbridge Health, describes the trial as a noteworthy advancement in affordable, remote cardiac care, stating, “The Cor Insight trial allows us to provide over 30 cardiac and cardiopulmonary indications all from one simple wearable ECG study.” He emphasizes that enabling low-cost hospital-grade diagnostics at home can help extend medical services to millions who currently face barriers to care.

Improving Access to Cardiac Care

One of the trial's foundational principles is enhancing accessibility across various patient demographics. The Peerbridge Cor wearable can function broadly, serving everyone from asymptomatic individuals to those with critical conditions awaiting surgeries like transcatheter aortic valve replacement (TAVR) and implantable cardioverter-defibrillator (ICD) placements. It aims to gather vital data across diverse environments, such as outpatient clinics, hospitals, and home settings.

By enrolling up to 15,000 diverse participants, the trial promises to gather robust data reflective of real-world clinical challenges. The involvement of prominent institutions like HCA and Mercy Health through the HeartX program will enhance the diversity and scope of the trial, targeting numerous patient demographics across various healthcare settings.

Potential Outcomes from the Trial

The COR-INSIGHT trial not only strives to make long-lasting changes in diagnostics but also envisions benefits such as:

• - Early Disease Detection: The ability to perform rapid screenings could yield critical early warnings for cardiac conditions, enabling healthcare providers to intervene before issues worsen.
• - Like Reducing Readmission Rates: Many heart failure patients face re-admissions shortly after discharge; remote monitoring allows healthcare teams to ensure stability from home and potentially reduce these rates.
• - Support for Virtual Appointments: Given that 90% of rural U.S. counties lack a cardiologist, the technology-enabled remote assessments prior to virtual appointments can greatly increase the reach and effectiveness of cardiology care.

Peerbridge Health continues to lead the way in redefining cardiac care with its innovative technologies, particularly the Cor wearable. With the COR-INSIGHT Trial underway, the company is poised to bring vital insights and lifesaving diagnostics directly to patients, enhancing healthcare engagement and outcomes for millions.

Conclusion

As Peerbridge Health embarks on this revolutionary journey in cardiac diagnostics, the COR-INSIGHT Trial carries the promise of innovation and accessibility. By harnessing AI and advanced wearable technologies, this initiative aims to transform the landscape of cardiovascular care, ultimately saving lives through improved monitoring and timely interventions. Stay connected to witness the evolution of cardiac diagnostics with Peerbridge Health's trailblazing advancements.